DK3011048T3 - Fremgangsmåde til at forudsige et behandlingsrespons til en v1b-antagonist hos en patient med depressions- og/eller angstsymptomer - Google Patents

Fremgangsmåde til at forudsige et behandlingsrespons til en v1b-antagonist hos en patient med depressions- og/eller angstsymptomer Download PDF

Info

Publication number
DK3011048T3
DK3011048T3 DK14736319T DK14736319T DK3011048T3 DK 3011048 T3 DK3011048 T3 DK 3011048T3 DK 14736319 T DK14736319 T DK 14736319T DK 14736319 T DK14736319 T DK 14736319T DK 3011048 T3 DK3011048 T3 DK 3011048T3
Authority
DK
Denmark
Prior art keywords
antagonist
predicting
depression
patient
procedure
Prior art date
Application number
DK14736319T
Other languages
Danish (da)
English (en)
Inventor
Florian Holsboer
Bertram Müller-Myhsok
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Application granted granted Critical
Publication of DK3011048T3 publication Critical patent/DK3011048T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK14736319T 2013-06-17 2014-06-16 Fremgangsmåde til at forudsige et behandlingsrespons til en v1b-antagonist hos en patient med depressions- og/eller angstsymptomer DK3011048T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1310782.6A GB201310782D0 (en) 2013-06-17 2013-06-17 Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms
PCT/EP2014/062592 WO2014202541A1 (en) 2013-06-17 2014-06-16 Method for predicting a treatment response to a crhr1 antagonist and/or a v1b antagonist in a patient with depressive and/or anxiety symptoms

Publications (1)

Publication Number Publication Date
DK3011048T3 true DK3011048T3 (da) 2019-11-04

Family

ID=48914695

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14736319T DK3011048T3 (da) 2013-06-17 2014-06-16 Fremgangsmåde til at forudsige et behandlingsrespons til en v1b-antagonist hos en patient med depressions- og/eller angstsymptomer

Country Status (8)

Country Link
US (2) US10190168B2 (enExample)
EP (2) EP3623483A1 (enExample)
JP (1) JP6689743B2 (enExample)
CA (1) CA2914866C (enExample)
DK (1) DK3011048T3 (enExample)
ES (1) ES2759507T3 (enExample)
GB (1) GB201310782D0 (enExample)
WO (1) WO2014202541A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201210686D0 (en) 2012-06-15 2012-08-01 Holsboermaschmeyer Neurochemie Gmbh V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level
GB201310782D0 (en) 2013-06-17 2013-07-31 Max Planck Innovation Gmbh Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms
AU2016240213B2 (en) * 2015-04-02 2022-01-27 HMNC Holding GmbH Method of treatment using genetic predictors of a response to treatment with CRHR1 antagonists
AU2016240212B2 (en) * 2015-04-02 2022-01-27 HMNC Holding GmbH Genetic predictors of a response to treatment with CRHR1 antagonists
WO2017035528A1 (en) * 2015-08-27 2017-03-02 Nantneuro, Llc Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau
CN113632174B (zh) 2019-01-23 2025-03-25 密歇根大学董事会 用于nmda、甘氨酸和ampa受体的调节剂的药物基因组学决策支持
WO2022200966A1 (en) * 2021-03-23 2022-09-29 Iluria Ltd. Diagnosis and monitoring medical treatment effectivness for anxiety and depression disorders

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0674641B1 (en) 1992-12-17 1999-03-03 Pfizer Inc. Pyrrolopyrimidines as crf antagonists
HUT74464A (en) 1993-10-12 1996-12-30 Du Pont Merck Pharma 1n-alkyl-n-arylpyrimidinamines and derivatives thereof, and pharmaceutical compositions containing them
TW574214B (en) 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
US5591588A (en) 1994-09-20 1997-01-07 Gideon Goldstein Method for the diagnosis of depression based on monitoring blood levels of arginine vasopressin and/or thymopoietin
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US7067664B1 (en) 1995-06-06 2006-06-27 Pfizer Inc. Corticotropin releasing factor antagonists
PL191271B1 (pl) 1996-02-07 2006-04-28 Neurocrine Biosciences Inc Pochodna pirazolopirymidyny i jej zastosowanie oraz kompozycja farmaceutyczna
EA006626B1 (ru) 1996-07-24 2006-02-24 Дюпон Фармасьютикалз Компани Азолопиримидины, фармацевтическая композиция и способ лечения
US6060478A (en) 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
FR2796380B3 (fr) 1999-07-15 2001-08-17 Sanofi Synthelabo Nouveaux derives d'aminothiazoles, leur preparation et les compositions pharmaceutiques les contenant
US20030092019A1 (en) * 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
ATE355102T1 (de) 2001-03-13 2006-03-15 Bristol Myers Squibb Pharma Co 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6- methoxypyrid-3-yl) pyrazolo- 1,5-aö-1,3,5-triazin,seine enantiomeren und pharmazeutisch annehmbare salze als corticotropin-releasing-factor-rezeptor-ligande
EP1514946A4 (en) 2002-05-17 2006-06-07 Riken METHOD FOR DETECTING GENE POLYMORPHISM
GR1004664B (en) 2002-11-26 2004-09-02 Bionature E A Ltd The charakteristics and advantages of our invention are illustrated by the following description, methods and results of our research, attached figures and supporting references
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
EP1659121A4 (en) 2003-08-28 2008-11-26 Taisho Pharmaceutical Co Ltd 1,3-dihydro-2H-indol-2-one derivative
US20050069936A1 (en) 2003-09-26 2005-03-31 Cornelius Diamond Diagnostic markers of depression treatment and methods of use thereof
US20080118918A1 (en) 2004-08-13 2008-05-22 The Regents Of The University Of California Compositions and Methods For Determining and Predicting Treatment Responses For Depression and Anxiety
EP1628136A1 (en) 2004-08-19 2006-02-22 B.R.A.H.M.S. Aktiengesellschaft Method of diagnosis of disease using copeptin
GB0519957D0 (en) 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
JP2008526702A (ja) * 2004-12-31 2008-07-24 アボット ゲーエムベーハー ウント カンパニー カーゲー 置換オキシインドール誘導体、該誘導体を含んでいる薬物及びそれらの使用
JP5125501B2 (ja) 2005-01-28 2013-01-23 大正製薬株式会社 1,3−ジヒドロ−2h−インドール−2−オン化合物、及び芳香族複素環が縮合したピロリジン−2−オン化合物
BRPI0711872A2 (pt) 2006-05-22 2011-12-06 Vanda Pharmaceuticals Inc tratamento para distúrbios depressivos
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
WO2009113985A1 (en) 2008-03-13 2009-09-17 Maria Athanasiou Genetic markers associated with response to antidepressants
WO2009130232A1 (en) 2008-04-24 2009-10-29 Glaxo Group Limited Pyrazolo [1, 5 -a] pyrazine derivatives as antagonists of v1b receptors
US9644240B2 (en) * 2009-10-22 2017-05-09 Leiden University Disease susceptibility
US20150278438A1 (en) 2012-04-23 2015-10-01 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Genetic predictors of response to treatment with crhr1 antagonists
EP2841068B8 (en) 2012-04-23 2019-03-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Crhr1 antagonists for use in the treatment of patients having crh overactivity
GB201210686D0 (en) * 2012-06-15 2012-08-01 Holsboermaschmeyer Neurochemie Gmbh V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level
GB201310782D0 (en) 2013-06-17 2013-07-31 Max Planck Innovation Gmbh Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms

Also Published As

Publication number Publication date
CA2914866A1 (en) 2014-12-24
JP2016521987A (ja) 2016-07-28
US10190168B2 (en) 2019-01-29
US10837062B2 (en) 2020-11-17
WO2014202541A1 (en) 2014-12-24
EP3011048B1 (en) 2019-08-07
CA2914866C (en) 2024-09-10
US20160153043A1 (en) 2016-06-02
EP3011048A1 (en) 2016-04-27
US20190194752A1 (en) 2019-06-27
ES2759507T3 (es) 2020-05-11
JP6689743B2 (ja) 2020-04-28
GB201310782D0 (en) 2013-07-31
EP3623483A1 (en) 2020-03-18

Similar Documents

Publication Publication Date Title
FI20120340L (fi) Kosketusrajapintalaite ja rakenne
DK3011048T3 (da) Fremgangsmåde til at forudsige et behandlingsrespons til en v1b-antagonist hos en patient med depressions- og/eller angstsymptomer
IL239822A0 (en) Appartus and methods for analyzing inhaled gas
IL244607A0 (en) Apparatus and method for determining physiologic perturbations of a patient
BR302013001430S1 (pt) Configuração aplicada à conjunto de interface de paciente
DK3076967T3 (da) Fremgangsmåder til behandling af residuelle symptomer på skizofreni
FI20126186A7 (fi) Järjestely ja menetelmä elektrodimittausten suorittamiseksi
GB2524446B (en) Method and device for determining the geometry of structures by means of computer tomography
DK2986624T3 (da) Neuroaktive 19-nor-steroider til terapeutisk anvendelse
EP3831439C0 (en) CONNECTION SYSTEM FOR MEDICAL DEVICE COMPONENTS
DK2934189T3 (da) Humane mælkeoligosaccharider til reduktion af stress-symptomer
EP3821931C0 (en) ORONASAL PATIENT INTERFACE
EP2922514A4 (en) BI-RADIAL PATIENT INTERFACE
DK2707029T3 (da) Fremgangsmåder til at behandle eller forebygge kolesterolrelaterede sygdomme
DK2988806T3 (da) Supplerende anordning til anvendelse sammen med en injektionsanordning
EP3005019A4 (en) COMPUTER INTERIOR DESIGN
DK2594587T3 (da) Anti-Adrenomedullin (ADM)-antistof eller anti-ADM-antistoffragment eller anti-ADM ikke-Ig-protein-scaffold til at reducere risikoen for mortalitet hos en patient med en kronisk eller akut sygdom eller akut tilstand
LT3054912T (lt) Su stresu susijusio miego sutrikimo lengvinimo ir žmogaus streso mažinimo būdas ir įrenginys
DK2869836T3 (da) Dna-vaccine til anvendelse hos patienter med pankreascancer
DK3041349T3 (da) Anordning til angrebsdiagnose
DK2964767T3 (da) Toksingener og fremgangsmåder til anvendelse deraf
EP3041440C0 (en) ORTHOPEDIC APPARATUS WITH INTERNAL SHOE FOR FOOT DROP AND SIMILAR CONDITIONS
EP2962741A4 (en) GOLF INSTRUMENT INSTALLATION SYSTEM AND GOLF INSTRUMENT INSTALLATION PROGRAM
PL3084012T3 (pl) Sposób wytapiania i urządzenie
EP2952844A4 (en) MONOLITHIC FIRE-RESISTANT STRUCTURE